GS-441524 in 17 retrovirus-positive cats with presumptive effusive FIP
Pathogens (Basel, Switzerland) · 2026
RESEARCH HYPOTHESIS — NOT A CLINICAL RECOMMENDATION
In plain language
This study reviewed caretaker survey data from 17 cats with FeLV and/or FIV treated with GS-441524 for presumptive effusive FIP. Reported survival was high in this small cohort, but the study does not prove that treatment caused those outcomes or define what to expect for all FeLV-positive cats. The data were survey-based, with presumptive diagnoses, unstandardized protocols, and unlicensed product use.
Scientific detail
This 2026 Pathogens article describes a clinical cohort of 17 retrovirus-positive cats, with FeLV and/or FIV, treated with GS-441524 for presumptive effusive FIP. Its relevance to FeLV is direct because FeLV-positive cats were included, although the abstract does not separate all outcomes by FeLV-only status versus other retroviral statuses.
Data were collected through caretaker surveys. In the reported cohort, the average starting GS-441524 dosage was 7 mg/kg/day, with dosage increases in 65% of cats and treatment extension in 35%. These findings describe use patterns and protocol modifications; they do not identify an optimal dose, prove the efficacy of dose escalation, or provide a treatment recommendation.
Among the 17 retrovirus-positive cats with presumptive FIP, three relapses were reported, twelve-week survival was 94% (16/17), and one-year survival was 82% (14/17). Seven cats were alive at follow-up a median of 1306 days after FIP diagnosis, while many cats died from neoplasia. These outcomes come from a small, uncontrolled cohort and do not establish causality or expected outcomes for all FeLV-positive cats.
The authors considered treatment success in retrovirus-positive cats with presumptive FIP to be similar to previously reported outcomes for FIP alone. That conclusion remains limited by presumptive diagnosis, survey-based data, noncurrent and unstandardized protocols, unlicensed product use, and the absence of a controlled comparison. The source identifies the need for additional studies, including the impact of FeLV proviral load.
What we know
The evidence supports that, in this small clinical cohort of 17 cats with FeLV and/or FIV and presumptive effusive FIP, treated with GS-441524 according to survey data, three relapses, 94% twelve-week survival, and 82% one-year survival were reported. It also supports that dosage increases and treatment extensions occurred in part of the cohort. These are level C data, uncontrolled, survey-based, and limited by protocol and product issues.
What we don't know
The ideal protocol, the role of FeLV proviral load, and whether these outcomes apply to all FeLV-positive cats are not known. The study does not prove causality, does not separate all outcomes for FeLV-only cats, does not uniformly confirm diagnosis, and does not provide a treatment recommendation.
Evidence
EvidenceLevel C — Preliminary evidenceConfidence 98/100
This study collected survey data from caretakers of FeLV- and/or FIV-positive cats treated with GS-441524 for presumptive effusive FIP.
Excerpt verified in the source — verbatim, in the source's own language“A survey was distributed to caretakers of cats with feline leukemia virus (FeLV) and/or feline immunodeficiency virus (FIV) that were treated with GS-441524 for presumptive effusive FIP based on survey responses.”
This establishes the survey-based design and population described by the source. It does not establish randomized allocation, diagnostic confirmation, or controlled comparison.
EvidenceLevel C — Preliminary evidenceConfidence 98/100
In the reported cohort, the average starting GS-441524 dosage was 7 mg/kg/day, with dosage increases in 65% of cats and treatment extension in 35%.
Excerpt verified in the source — verbatim, in the source's own language“The average starting dosage (7 mg/kg/d) was increased in 65% of cats, and treatment was extended in 35%.”
This reports dosing and protocol modification patterns in the surveyed cats. It does not identify an optimal dose, prove efficacy of dose escalation, or provide a treatment recommendation.
EvidenceLevel C — Preliminary evidenceConfidence 99/100Awaiting human review
Among the 17 retrovirus-positive cats with presumptive FIP, three cats relapsed, twelve-week survival was 94% (16/17), and one-year survival was 82% (14/17).
Excerpt verified in the source — verbatim, in the source's own language“Three cats relapsed (18%). There was a 94% (16/17) twelve-week survival rate and 82% (14/17) one-year survival rate.”
This directly reports relapse and survival outcomes in this small, uncontrolled cohort. It does not prove causality or establish expected outcomes for all FeLV-positive cats.
EvidenceLevel C — Preliminary evidenceConfidence 98/100Awaiting human review
Seven cats were alive at follow-up a median of 1306 days after FIP diagnosis, while many cats died from neoplasia.
Excerpt verified in the source — verbatim, in the source's own language“Seven cats were alive at follow-up, a median of 1306 days (range 983-2069) after FIP diagnosis, but many cats succumbed to neoplasia.”
This describes long-term follow-up status and a reported cause category of mortality. It does not quantify neoplasia incidence or separate outcomes by FeLV versus FIV.
EvidenceLevel C — Preliminary evidenceConfidence 97/100Awaiting human review
The authors considered treatment success in retrovirus-positive cats with presumptive FIP similar to previously reported outcomes for FIP alone, while noting protocol and product limitations.
Excerpt verified in the source — verbatim, in the source's own language“Treatment success for retrovirus-positive cats with presumptive FIP was similar to previously reported outcomes for FIP alone. This could support current evidence of successful antiviral therapy for similar populations, if noncurrent, unstandardized protocols and unlicensed product use are considered.”
This is the authors' conclusion from the reported cohort. It does not override the limitations of presumptive diagnosis, survey-based data, lack of controls, unstandardized protocols, or unlicensed product use.
Open questionConfidence 99/100
Additional studies are needed to determine ideal protocols and the impact of FeLV proviral load in retrovirus-positive cats with FIP.
The source explicitly identifies unresolved research needs. This should not be read as evidence for any specific protocol, dose, duration, or clinical recommendation.
Provenance
Source: Clinical Features and Outcomes of Treatment for Effusive Feline Infectious Peritonitis with GS-441524 in Seventeen Retrovirus-Positive Cats.
AVA